Highlights at the end of September 30, 2016 : Total cumulated revenue in 2016 up 22% year-over-year; Driven by HIFU growth, Gross Margin increases to 45%; 111% growth in HIFU revenues in Q3 of 2016 compared to Q3 2015; Company continues to show operating profit in 2016 at the end of Q3; Strong
LYON, France , Oct. 11, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the results of a multicentric study using Ablatherm Robotic HIFU which demonstrates promising oncologic outcomes with low side effects.
LYON, France , Sept. 12, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the signature of a contract for the installation of Ablatherm Robotic HIFU at the renowned Duke University Hospital located in Durham, North Carolina .
LYON, France , Sept. 06, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that Marc Oczachowski , Chief Executive Officer of EDAP TMS , is scheduled to present at the 18 th Annual Rodman & Renshaw Global Investment Conference being
Total EDAP revenue up 20.4% year-over-year in the first six months of 2016 Continued growth in HIFU system sales and treatment-driven revenue with strong margins Focal One® 510k under FDA review Solid cash position at €21.9 million as of June 30, 2016 LYON, France , Aug.
LYON, France , Aug. 22, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Henry Ford Hospital in Detroit, Michigan , using the Company's FDA-cleared Ablatherm Robotic HIFU.
Ablatherm Robotic HIFU Deployed by HIFU USA; Initial Treatments Performed in New York by Dr. Ron Israeli and in New England by Drs. Clifford Gluck and James Lin
